Ingunn Holen
Ingunn Holen
Email verificata su - Home page
Citata da
Citata da
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ...
Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ...
Breast Cancer Research 15 (5), 1-37, 2013
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
I Holen, PI Croucher, FC Hamdy, CL Eaton
Cancer research 62 (6), 1619-1623, 2002
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
MC Winter, I Holen, RE Coleman
Cancer treatment reviews 34 (5), 453-475, 2008
Tumour macrophages as potential targets of bisphosphonates
TL Rogers, I Holen
Journal of translational medicine 9 (1), 177, 2011
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
PD Ottewell, H Mnkknen, M Jones, DV Lefley, RE Coleman, I Holen
Journal of the National Cancer Institute 100 (16), 1167-1178, 2008
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
M Coscia, E Quaglino, M Iezzi, C Curcio, F Pantaleoni, C Riganti, I Holen, ...
Journal of cellular and molecular medicine 14 (12), 2803-2815, 2010
Sequence‐and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
HL Neville‐Webbe, A Rostami‐Hodjegan, CA Evans, RE Coleman, ...
International journal of cancer 113 (3), 364-371, 2005
Dependence of hepatocytic autophagy on intracellularly sequestered calcium.
PB Gordon, I Holen, M Fosse, JS Rtnes, PO Seglen
Journal of Biological Chemistry 268 (35), 26107-26112, 1993
Optimizing the yield and utility of circulating cell-free DNA from plasma and serum
X Xue, MD Teare, I Holen, YM Zhu, PJ Woll
Clinica chimica acta 404 (2), 100-104, 2009
Multidrug resistance in breast cancer: from in vitro models to clinical studies
NS Wind, I Holen
International journal of breast cancer 2011, 2011
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis
HL Neville-Webbe, NA Cross, CL Eaton, R Nyambo, CA Evans, ...
Breast cancer research and treatment 86 (3), 271-282, 2004
The anti-tumour activity of bisphosphonates
HL Neville-Webbe, I Holen, RE Coleman
Cancer treatment reviews 28 (6), 305-319, 2002
Expression and activity of ADAMTS‐5 in synovium
MN Vankemmelbeke, I Holen, AG Wilson, MZ Ilic, CJ Handley, GS Kelner, ...
European Journal of Biochemistry 268 (5), 1259-1268, 2001
Role of osteoprotegerin (OPG) in cancer
I Holen, CM Shipman
Clinical science 110 (3), 279-291, 2006
Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?
I Holen, SS Cross, HL Neville-Webbe, NA Cross, SP Balasubramanian, ...
Breast cancer research and treatment 92 (3), 207-215, 2005
The detection of circulating breast cancer cells in blood
AM Gilbey, D Burnett, RE Coleman, I Holen
Journal of clinical pathology 57 (9), 903-911, 2004
Pathophysiological roles of osteoprotegerin (OPG)
P Reid, I Holen
European journal of cell biology 88 (1), 1-17, 2009
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis
A Thompson, K Brennan, A Cox, J Gee, D Harcourt, A Harris, M Harvie, ...
Breast Cancer Research 10 (2), R26, 2008
Disruption of the cytokeratin cytoskeleton and inhibition of hepatocytic autophagy by okadaic acid
H Blankson, I Holen, PO Seglen
Experimental cell research 218 (2), 522-530, 1995
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20